Hopital Prive Jean Mermoz
- Address
- lock Available on a paid plan
Hopital Prive Jean Mermoz - Comprehensive Oncology Research Center
Hopital Prive Jean Mermoz is a leading clinical research institution specializing in advanced oncology therapeutics and precision medicine approaches. The center demonstrates extensive expertise across a broad spectrum of gastrointestinal malignancies, breast cancer, and thoracic oncology, with particular focus on innovative immunotherapy combinations and targeted molecular therapies.
- Gastrointestinal cancers including colorectal, gastric, gastroesophageal junction, pancreatic, anal, and biliary tract adenocarcinomas with emphasis on precision medicine and biomarker-driven treatment strategies
- Breast cancer across all molecular subtypes (HER2+, triple-negative, hormone receptor-positive) including neoadjuvant, adjuvant, and metastatic settings with advanced targeted therapies and immunotherapy combinations
- Ovarian and gynecologic malignancies focusing on PARP inhibitors, immunotherapy, and personalized maintenance strategies
- Non-small cell lung cancer with novel immunotherapy regimens and chemoimmunotherapy combinations for advanced disease
The center participates in numerous phase II and III trials investigating cutting-edge treatment modalities including CDK4/6 inhibitors, checkpoint inhibitor combinations, and antibody-drug conjugates. Research initiatives emphasize de-escalation strategies in responding patients, circulating tumor DNA-guided therapy decisions, and biomarker-selected targeted approaches including HER2-directed therapies, KRAS G12C inhibitors, and treatments for microsatellite instability-high tumors. The institution plays a key role in evaluating perioperative treatment strategies and maintenance therapy optimization across multiple tumor types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 131 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 129 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Prive Jean Mermoz
lock Showing 1 of 92 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 131 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 31 | Unknown | 2014-12-23 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.